vs
Side-by-side financial comparison of Commerce.com, Inc. (CMRC) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Commerce.com, Inc. is the larger business by last-quarter revenue ($89.5M vs $86.8M, roughly 1.0× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 2.9%). Commerce.com, Inc. produced more free cash flow last quarter ($-2.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 5.5%).
SPS Commerce, Inc. is a technology and application software company based in the United States that provides cloud-based supply chain management software. The company's headquarters are located in Minneapolis, Minnesota, but it also has a US office in New Jersey, and international locations in Amsterdam, Beijing, Breukelen, Hong Kong, Kyiv, Melbourne, Montpellier, Sydney, and Toronto.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CMRC vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $89.5M | $86.8M |
| Net Profit | $-8.4M | — |
| Gross Margin | 78.3% | 67.4% |
| Operating Margin | -7.4% | -84.7% |
| Net Margin | -9.3% | — |
| Revenue YoY | 2.9% | 17.7% |
| Net Profit YoY | -250.0% | — |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $89.5M | $86.8M | ||
| Q3 25 | $86.0M | $67.5M | ||
| Q2 25 | $84.4M | $60.0M | ||
| Q1 25 | $82.4M | $49.3M | ||
| Q4 24 | $87.0M | $73.7M | ||
| Q3 24 | $83.7M | $58.6M | ||
| Q2 24 | $81.8M | $31.1M | ||
| Q1 24 | $80.4M | $715.0K |
| Q4 25 | $-8.4M | — | ||
| Q3 25 | $-2.2M | $-91.3M | ||
| Q2 25 | $-8.4M | $-111.7M | ||
| Q1 25 | $-353.0K | $-116.2M | ||
| Q4 24 | $-2.4M | — | ||
| Q3 24 | $-7.0M | $-83.5M | ||
| Q2 24 | $-11.3M | $-97.1M | ||
| Q1 24 | $-6.4M | $-113.0M |
| Q4 25 | 78.3% | 67.4% | ||
| Q3 25 | 78.4% | 43.0% | ||
| Q2 25 | 79.0% | 5.5% | ||
| Q1 25 | 79.4% | -0.8% | ||
| Q4 24 | 77.6% | 68.7% | ||
| Q3 24 | 76.3% | 46.2% | ||
| Q2 24 | 75.8% | -0.8% | ||
| Q1 24 | 77.1% | — |
| Q4 25 | -7.4% | -84.7% | ||
| Q3 25 | -0.5% | -140.7% | ||
| Q2 25 | -8.0% | -189.8% | ||
| Q1 25 | -2.9% | -245.8% | ||
| Q4 24 | -0.9% | -117.5% | ||
| Q3 24 | -23.0% | -152.1% | ||
| Q2 24 | -16.5% | -327.6% | ||
| Q1 24 | -10.2% | -16464.6% |
| Q4 25 | -9.3% | — | ||
| Q3 25 | -2.6% | -135.3% | ||
| Q2 25 | -9.9% | -186.2% | ||
| Q1 25 | -0.4% | -235.5% | ||
| Q4 24 | -2.7% | — | ||
| Q3 24 | -8.4% | -142.7% | ||
| Q2 24 | -13.8% | -312.2% | ||
| Q1 24 | -8.0% | -15800.8% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-0.10 | $-0.33 | ||
| Q1 25 | $0.00 | $-0.36 | ||
| Q4 24 | $-0.03 | $-0.24 | ||
| Q3 24 | $-0.09 | $-0.28 | ||
| Q2 24 | $-0.15 | $-0.34 | ||
| Q1 24 | $-0.08 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $141.1M | $297.0M |
| Total DebtLower is stronger | $157.0M | — |
| Stockholders' EquityBook value | $39.4M | $698.6M |
| Total Assets | $308.8M | $913.2M |
| Debt / EquityLower = less leverage | 3.99× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $141.1M | $297.0M | ||
| Q3 25 | $142.0M | $300.8M | ||
| Q2 25 | $134.5M | $301.2M | ||
| Q1 25 | $120.7M | $359.7M | ||
| Q4 24 | $178.2M | $323.8M | ||
| Q3 24 | $168.4M | $397.5M | ||
| Q2 24 | $275.8M | $412.5M | ||
| Q1 24 | $265.2M | $356.2M |
| Q4 25 | $157.0M | — | ||
| Q3 25 | $157.3M | — | ||
| Q2 25 | $157.5M | — | ||
| Q1 25 | $157.8M | — | ||
| Q4 24 | $216.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $340.9M | — | ||
| Q1 24 | $340.5M | — |
| Q4 25 | $39.4M | $698.6M | ||
| Q3 25 | $42.8M | $702.3M | ||
| Q2 25 | $38.8M | $698.5M | ||
| Q1 25 | $38.1M | $767.9M | ||
| Q4 24 | $33.4M | $710.4M | ||
| Q3 24 | $29.0M | $773.5M | ||
| Q2 24 | $26.1M | $768.5M | ||
| Q1 24 | $26.9M | $680.0M |
| Q4 25 | $308.8M | $913.2M | ||
| Q3 25 | $309.5M | $904.9M | ||
| Q2 25 | $302.5M | $907.4M | ||
| Q1 25 | $286.3M | $966.7M | ||
| Q4 24 | $340.3M | $910.4M | ||
| Q3 24 | $335.1M | $991.1M | ||
| Q2 24 | $452.5M | $964.3M | ||
| Q1 24 | $442.5M | $869.8M |
| Q4 25 | 3.99× | — | ||
| Q3 25 | 3.67× | — | ||
| Q2 25 | 4.06× | — | ||
| Q1 25 | 4.14× | — | ||
| Q4 24 | 6.49× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 13.06× | — | ||
| Q1 24 | 12.65× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $980.0K | $-52.6M |
| Free Cash FlowOCF − Capex | $-2.2M | $-61.9M |
| FCF MarginFCF / Revenue | -2.4% | -71.3% |
| Capex IntensityCapex / Revenue | 3.5% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $16.9M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $980.0K | $-52.6M | ||
| Q3 25 | $10.6M | $-78.7M | ||
| Q2 25 | $13.6M | $-67.4M | ||
| Q1 25 | $401.0K | $-103.7M | ||
| Q4 24 | $12.4M | $-73.3M | ||
| Q3 24 | $5.6M | $-59.0M | ||
| Q2 24 | $11.7M | $-98.4M | ||
| Q1 24 | $-3.4M | $-122.3M |
| Q4 25 | $-2.2M | $-61.9M | ||
| Q3 25 | $7.6M | $-89.5M | ||
| Q2 25 | $11.9M | $-74.9M | ||
| Q1 25 | $-424.0K | $-109.9M | ||
| Q4 24 | $11.6M | $-77.5M | ||
| Q3 24 | $4.5M | $-61.3M | ||
| Q2 24 | $10.7M | $-98.9M | ||
| Q1 24 | $-4.2M | $-126.5M |
| Q4 25 | -2.4% | -71.3% | ||
| Q3 25 | 8.8% | -132.7% | ||
| Q2 25 | 14.1% | -124.9% | ||
| Q1 25 | -0.5% | -222.8% | ||
| Q4 24 | 13.3% | -105.1% | ||
| Q3 24 | 5.4% | -104.6% | ||
| Q2 24 | 13.0% | -317.9% | ||
| Q1 24 | -5.3% | -17685.3% |
| Q4 25 | 3.5% | 10.7% | ||
| Q3 25 | 3.4% | 16.1% | ||
| Q2 25 | 2.0% | 12.4% | ||
| Q1 25 | 1.0% | 12.6% | ||
| Q4 24 | 0.9% | 5.7% | ||
| Q3 24 | 1.3% | 3.9% | ||
| Q2 24 | 1.3% | 1.4% | ||
| Q1 24 | 1.0% | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMRC
| Subscription And Circulation | $65.2M | 73% |
| Partner And Services | $24.4M | 27% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
